Summary Tumour growth is dependent on angiogenesis. Vascular endothelial growth factor (VEGF) is a secreted endothelial cell-specific cytokine. VEGF is angiogenic in vivo and it also acts as a vascular permeability factor. VEGF is overexpressed in many skin disorders characterized by angiogenesis and increased vascular permeability. We Folkman, 1996) . One such stimulus is vascular endothelial growth factor (VEGF), which is a secreted, dimeric 46-kDa protein active as an endothelial cellspecific mitogen and as a vascular permeability factor. VEGF expression has been detected in a large variety of malignant human tumours, and it has been concluded that VEGF has an important role in tumour biology and in the process of tumour angiogenesis (reviewed in Dvorak et al, 1995; Ferrara, 1995) . VEGF mRNA has also been detected in metastatic melanoma cells in cerebral melanoma metastases (Hatva et al, 1995) .
Angiogenesis, the formation of new capillaries, is an important component in many biological processes and also pathological conditions, such as rheumatoid arthritis, diabetic retinopathy, wound healing and neoplastic diseases (reviewed in Folkman, 1995) . The growth of all solid tumours is dependent on the formation of new blood vessels. During tumorigenesis, the quiescent vasculature can become activated to grow new capillaries in response to an appropriate stimulus (reviewed in Hanahan and Folkman, 1996) . One such stimulus is vascular endothelial growth factor (VEGF), which is a secreted, dimeric 46-kDa protein active as an endothelial cellspecific mitogen and as a vascular permeability factor. VEGF expression has been detected in a large variety of malignant human tumours, and it has been concluded that VEGF has an important role in tumour biology and in the process of tumour angiogenesis (reviewed in Dvorak et al, 1995; Ferrara, 1995) . VEGF mRNA has also been detected in metastatic melanoma cells in cerebral melanoma metastases (Hatva et al, 1995) .
Progression of melanoma is supposed to be associated with an angiogenic response, and several histological studies have shown an increase in vascular structures in malignant melanoma, which is not the case in common naevocellular naevi (reviewed in Denijn and Ruiter, 1993) . Expression of VEGF in mouse VEGF cDNAtransected melanoma cells is associated with increased tumour growth, angiogenesis and experimental metastasis in vivo in a nude mouse model (Claffey et al, 1996) . This suggests a role for VEGF as a positive regulatory stimulus in angiogenesis, progression and dissemination of malignant melanoma. The aim of the present study was to investigate the expression of VEGF in normal dermis, naevocellular naevi and in primary and metastatic melanoma and to study the relationship between VEGF expression and tumour microvessel density, patient survival and other clinicopathological variables.
MATERIALS AND METHODS Patients and tissue samples
The study includes six patients with a common naevocellular naevus and 55 randomly selected patients with histologically diagnosed malignant melanoma treated with surgery and chemotherapy or chemoimmunotherapy in Helsinki University Central Hospital, during the time period from 1989 to 1995. The prognostic significance of VEGF expression was investigated in a series of 33 patients with a lymph node metastasis from malignant melanoma. Twenty of the patients with metastatic melanoma were male and 13 were female; age at the time of surgery ranged from 30 to 84 years (median 56 years). All patients with metastatic disease were followed up until death or for at least 4 years, as calculated from the surgical removal of the lymph node metastasis. The overall 2-year survival was 35% and 4-year survival 24%.
Determination of VEGF expression VEGF expression was determined using a mouse monoclonal antihuman VEGF antibody (MAB293, IgG2b, R&D Research, MN, USA) raised against the 165 amino acid species of the polypeptide. The 5-,um frozen sections were rehydrated, incubated for 30 min in 0.3% hydrogen peroxidase in methanol at room temperature and for 20 min in 5% normal horse serum at room temperature. The sections were incubated overnight at 4°C with the primary antibody 
Assessment of intratumoral microvessel density
The microvessel densities of the tumour samples were determined using two established vascular markers, the von Willebrand factor (vWF) and CD31 (PECAM-1). After incubating the slides for 20 min with 2% normal horse serum, the endothelial cells were stained with a monoclonal anti-vWF antibody (Dako, Denmark) using a dilution of 1:50, or monoclonal anti-CD3 1 antibody (Dako) using a dilution of 1:50, incubating overnight at +4'C. A subsequent incubation for 30 min in biotinylated anti-mouse serum was followed by a 30-min incubation using reagents of the Vectastain Elite ABC kit (Vector), developed with 3-amino-9-ethyl carbazole (Sigma) for 10 min and counterstained with haematoxylin for 5 min. Vascularity was defined as previously described (Weidner et al, 1991) by counting the number of vessels per a 400x magnification field in the areas with the highest vascular density ('vascular hotspots'). A minimum of five fields was counted and the three highest counts were averaged. The guidelines recommended by Gasparini and Harris (1995) were followed.
Assessment of intratumoral inflammatory infiltrate
The inflammatory infiltrates in the melanoma metastases were assessed using an anti-CD45RB antibody. This antibody reacts with B-and T-cells, monocytes, macrophages and weakly with granulocytes. After incubating the slides for 20 min with 2% normal horse serum, the slides were stained with a monoclonal mouse anti-human CD45RB antibody (clone PD7/26, Dako) using a dilution of 1:500, incubating for 1 h at room temperature. A subsequent incubation for 30 min in biotinylated anti-mouse serum was followed by a 30-min incubation using the reagents of the Vectastain Elite ABC kit (Vector), developed with 3-amino-9-ethyl carbazole (Sigma) for 10 min and counterstained with haematoxylin for 5 min. Figure IC ).
VEGF in melanoma metastases
Cytoplasmic staining of melanoma cells for VEGF was observed in 30 out of the 33 melanoma metastases (91%). The proportion of the stained melanoma cells ranged from 0% to 60% (median 3%, mean 9%; Table 1, Figure IE and F) . Thus, the proportion of tumours with melanoma cells staining for VEGF was higher in the metastases than in the primary cutaneous melanomas (30 out of 33 vs 7 out of 22, P < 0.0001). A part of the tumour-infiltrating Figure IG and H) . A constant staining for VEGF was also found in the endothelial cells of tumour microvessels (arrows in Figure IF) . A high amount of VEGF-expressing tumour-infiltrating inflammatory cells in a metastasis was found to be associated with a high percentage of VEGF-expressing melanoma cells (P = 0.003, tested minimal vs moderate or marked number of VEGF-positive inflammatory cells). Expression of VEGF in melanoma cells or in inflammatory cells was not associated with the total number of inflammatory cells in the tumour, as assessed using the anti-CD45 antibody (P > 0.1, tested minimal vs moderate or marked number of CD45-positive inflammatory cells).
VEGF expression and microvessel density
The microvessel counts obtained by staining for vWF and CD31 were strongly associated (P = 0.0003). However, the anti-CD31 antibody constantly stained more vascular structures than the antivWF antibody (median 33, range 15-67 vs median 26, range 9-56 respectively; P = 0.02). No associations were found between the microvessel densities obtained using the anti-CD31 antibody or the anti-vWF antibody and melanoma cell VEGF expression (P > 0.1 for both comparisons, tested < median vs > median).
VEGF expression and clinicopathological parameters
Among the primary cutaneous melanomas (n = 22), no differences could be observed in the VEGF expression when thin and thick primary melanomas were compared (P> 0.1, tested < median vs > median, 1 mm). The association between VEGF expression in lymph node metastases (n = 33) and prognosis was studied in a univariate survival analysis. The median (3%) and the highest quartile (10%) percentages of melanoma cell VEGF expression were used as cut-off values. No associations between VEGF expression and overall survival were found in the analyses (P> 0.1 for both comparisons). Similarly, no associations were found between the extent of tumour necrosis (tested present, n = 16 vs absent, n = 17) or the size of the metastasis (tested < median vs > median, 30 mm) and melanoma cell VEGF expression (P > 0.1 for both comparisons).
DISCUSSION
Studies in human melanoma cell lines xenografted to nude mice have suggested that VEGF plays a role in angiogenesis and progression of malignant melanoma (Potgens et al, 1995; Claffey et al, 1996) . We observed strong cytoplasmic staining for VEGF in melanoma cells in as many as 91% of the melanoma metastases. In contrast to metastatic melanoma, only 32% of the primary cutaneous melanomas had detectable VEGF expression in melanoma cells and only one of the primary melanomas showed staining in more than 5% of the melanoma cells. No immunoreactivity for VEGF could be detected in cells of naevocellular naevi or the histologically normal dermis.
We found immunostaining for VEGF in endothelial cells in both malignant and benign samples. Similar findings have been published for tumour blood vessels. These studies showed by immunohistochemistry that vascular endothelial cells stained strongly for VEGF but did not express detectable levels of VEGF mRNA by in situ hybridization, indicating that immunohistochemical staining of tumour vessels with antibodies to VEGF peptides reflects binding of VEGF secreted by adjacent cells (Duorak et al, 1991; Brown et al, 1993) .
Low amounts of VEGF mRNA have also been detected in the normal skin (Brown et al, 1992; Weninger et al, 1996) . Our finding of accumulation of VEGF on the vascular endothelium in the histologically normal dermis suggests that a constitutive low level VEGF expression may regulate skin vessel function under normal physiological conditions. Overexpression of VEGF has been reported in skin disorders that are characterized by angiogenesis and increased vascular permeability (Brown et al, 1995a) . VEGF is strongly expressed by epidermal keratinocytes in wound healing and psoriasis, both accompanied by angiogenesis and increased microvascular permeability (Brown et al, 1992; Detmar et al, 1994) . In delayed hypersensitivity skin reactions, which are also characterized by microvascular hyperpermeability, in situ hybridization revealed that the mRNAs encoding VEGF were strikingly overexpressed in keratinocytes of the epidermis (Brown et al, 1995b) . Weninger et al (1996) recently detected VEGF mRNA in the cells of common warts, squamous cell carcinomas and keratoacanthomas using in situ hybridization, and the VEGF mRNA expression was paralleled by VEGF immunostaining.
The angiogenetic activity and increased vascular permeability observed in the previously described disorders was accompanied by strong up-regulation or overexpression of VEGF mRNA when analysed by in situ hybridization. Because of the inability of immunohistochemistry to detect small amounts of soluble proteins, the VEGF immunoreactivity that we found in the few primary melanomas and in the majority of the metastatic melanomas probably reflects a population of melanoma cells expressing high levels of VEGF. Recent data indicate that the amount of VEGF may be crucial for its function, as studies with heterozygous and homozygous VEGF-deficient transgenic mice suggest a tight dose-dependent regulation of embryonic vessel development by VEGF (Carmeliet et al, 1996; Ferrara et al, 1996) .
We found VEGF-expressing tumour-infiltrating inflammatory cells in every melanoma sample studied. In line with our results, lymphocytes infiltrating human prostate or bladder cancers, peripheral blood T-lymphocytes and also scattered mononuclear cells infiltrating the dermis in delayed hypersensitivity skin reactions have been found to express VEGF (Brown et al, 1995b; Freeman et al, 1995) . Our results indicate that up-regulation of VEGF expression in metastatic melanoma cells is associated with elevation in the number of tumour-infiltrating inflammatory cells expressing VEGF. The results suggest a possible role for the VEGF-expressing tumourinfiltrating inflammatory cells in angiogenesis. Interestingly, in mice inoculated with melanoma cells, doxorubicin induced tumour growth retardation and a decrease in peritumoral vascularity that was associated with the degree of myelosuppression monitored by counting bone marrow cells, circulating leucocytes and peritoneal macrophages (Gutman et al, 1994) . The decrease in peritumoral vascularity might in part result from a possible direct effect of the drug on endothelial cells. Nevertheless, it is attractive to speculate that in addition to the direct anti-tumour effects, cancer chemotherapy may produce retardation of tumour growth by producing myelosuppression and hence inhibition of inflammatory cell-induced, VEGF-mediated tumour angiogenesis.
VEGF has been shown to be induced by hypoxia in vitro (Shweiki et al, 1992) and in vivo (Banai et al, 1994) . When melanoma cell lines expressing in vitro high or low levels of VEGF mRNA were xenografted into nude mice, the difference between VEGF mRNA expression levels disappeared in vivo. In all xenografts, equally high levels of VEGF mRNA were found, independent of the VEGF expression in the parental cell line (Potgens et al, 1995) . Similarly, in xenografted tumours in nude mice in vivo, concomitantly with invasion of new blood vessels and restoration of normoxia in the implanted tumour, VEGF expression was gradually down-regulated to a constitutive low level of expression, representing the output of non-stressed tumour cells (Shweiki et al, 1995) . Expression of VEGF in our series did not correlate with the primary melanoma thickness, microvessel density or patient survival in metastatic disease; this may be a reflection of the same phenomenon when hypoxia and possibly also other factors regulate the expression of VEGF in a reversible manner. Therefore, tumours with a dense microvasculature may sometimes express only low levels of VEGF, and tumours with a low microvessel density may display high levels of VEGF biosynthesis at a time when the vascular supply becomes inadequate. However, the prognostic significance of VEGF expression in primary melanoma requires further study.
Taken together, our results suggest that a constitutive low level expression of VEGF may regulate skin vessel function under the normal physiological conditions. The results are compatible with up-regulation of VEGF expression during melanoma tumorigenesis, progression and dissemination, suggesting an elementary role for VEGF in the angiogenic response necessary for melanoma growth and metastasis formation. The hyperpermeability of the newly formed blood vessels caused by VEGF (discussed in Dvorak et al, 1995) may be an essential factor in the metastatic process of the primary cutaneous melanoma. Expression of VEGF in tumour-infiltrating inflammatory cells may indicate that these cells contribute to angiogenesis and progression of malignant melanoma. Our observations also suggest that VEGF is a potential target for anti-angiogenic tumour therapy in melanoma.
